77例拉莫三嗪不良反应的文献分析

中国药物警戒 ›› 2016, Vol. 13 ›› Issue (5): 303-305.

• 安全性评估与合理用药 • 上一篇下一篇

77例拉莫三嗪不良反应的文献分析

何心,张永,徐进,许静

南京医科大学附属南京儿童医院药学部，江苏南京 210008

收稿日期:2015-12-25 修回日期:2016-06-30 出版日期:2016-05-20 发布日期:2016-06-30
通讯作者: 许静，女，副主任药师，硕士，医院药学。E-mail:njxujing@163.com
作者简介:何心，女，药师，硕士，临床药学。

Literature Review of 77 Cases of Adverse Drug Reactions Induced by Lamotrigine

HE Xin, ZHANG Yong, XU Jin, XU Jing

Deptartment of Pharmacy, Nanjing Children’s Hospital Affiliated to Nanjing Medical University, Jiangsu Nanjing 210008, China

Received:2015-12-25 Revised:2016-06-30 Online:2016-05-20 Published:2016-06-30

摘要/Abstract

摘要： 目的探讨拉莫三嗪致不良反应的一般规律和临床特点，为临床合理用药提供参考。方法检索1994～2014年间国内外医药期刊公开报道的拉莫三嗪致不良反应的个案报道，并进行统计分析。结果个案报道共检索到77例，Stevens-Johnson 综合征死亡3例，急性肝衰竭死亡1例。不良反应主要以皮肤损害为主，其所致不良反应可能与患者性别、年龄、联合用药等有一定的关联。结论临床应用拉莫三嗪时，应关注患者性别、年龄、药物相互作用及给药剂量，高度重视其所致的不良反应，确保用药安全。

关键词: 拉莫三嗪, 药品不良反应, 文献分析

Abstract: Objective To investigate the general rules of lamotrigine(LTG)-related adverse drug reactions(ADRs) and clinical characteristics, and to promote rational use of LTG. Methods Literatures of LTG-induced ADRs reported in domestic and overseas pharmaceutical journals from 1994 to 2014 were retrieved and analyzed. Results 77 cases were collected in which three patients died for Stevens-Johnson syndrome and one for acute liver failure. Most of LTG-related ADRs were skin lesions which may relate to the gender, age and combination use of drugs. Conclusion It is recommended to consider the gender, age, dose, and combination use of drugs when using LTG. More attention should be paid to LTG-related ADRs to promote its rational use.

Key words: lamotrigine, adverse durg reactions, literature review

中图分类号:

R994.11

何心,张永,徐进,许静. 77例拉莫三嗪不良反应的文献分析[J]. 中国药物警戒, 2016, 13(5): 303-305.

HE Xin, ZHANG Yong, XU Jin, XU Jing. Literature Review of 77 Cases of Adverse Drug Reactions Induced by Lamotrigine[J]. Chinese Journal of Pharmacovigilance, 2016, 13(5): 303-305.

参考文献

[1] Norio Y F, Kojiro H, Koji T, et al. Comorbidity of Stevens Johnson syndrome and neutropenia associated with lamotrigine: a case report [J]. Gen Hosp Psychiatry, 2014, 36(6) : 761.e9-761.e11.
[2] Meldrum B. Action of established and novel anticonvulsant drugs on the basic mechanisms of epilepsy [J]. Epilepsy Res Suppl, 1996,11(7):67-77.
[3] 刘文丽，李红健，于鲁海，等. 拉莫三嗪致斯－约综合征及相关文献分析[J]. 中国医院药学杂志,2012,32(18): 1490-1493.
[4] 刘立民，江丹，庞露，等. 拉莫三嗪药动学及其影响因素研究进展[J]. 医药导报,2013,12(32): 1616-1619.
[5] Stefani A, Spadoni F, Siniscalchi A, et al. Lamotrigine inhibits Ca2+ currents in cortical neurons: functional implications [J]. Eur J Pharmacol, 2006, 307(1): 113-116.
[6] Sarco D P, Bourgeois B F. The safety and tolerability of newer antiepileptic drugs in children and adolescents [J]. CNS Drugs, 2010, 24(5): 399-430.
[7] Wong I C, Mawer G E, Sander J W. Factors influencing the incidence of lamotrigine-related skin rash [J]. Ann Pharmacother, 1999, 33(10): 1037-1042.
[8] Silje A, Stian L, Eylert B. Rash from Antiepileptic Drugs: Influence by Gender, Age, and Learning Disability [J]. Epilepsia, 2007, 48(7): 1360-1365.
[9] Hirsch L J, Weintraub D B, Buchsbaum R, et al. Predictors of lamotrigine-associated rash [J]. Epilepsia, 2006, 47(2):318-322.
[10] Chung W H, Hung S I, Hong H S, et al. Medical genetics: a marker for Stevens-Johnson syndrome [J]. Nature，2004,428(6982):486.
[11] An D M, Wua X T, Hua F Y, et al. Association study of lamotrigine-induced cutaneous adverse reactions and HLA-B*1502 in a Han Chinese population [J]. Epilepsy Res, 2010, 92(2-3):226-230.
[12] Lonjou C, Borot N, Sekula P, et al. A european study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs[J]. Pharmacogenet Genomics,2008,18(2): 99-107.
[13] Kazeem G R, Cox C, Aponte J, et al. High-resolution HLA genotyping and severe cutaneous adverse reactions in lamotrigine-treated patients[J]. Pharmacogenet Genomics,2009,19(9): 661-665.
[14] Pellock J M. Overview of lamotrigine and the new antiepileptic drugs:the challenge[J]. J Child Neurol, 2007,12(1): S48-S52.
[15] Stefan H, Feuerstein T J. Novel anticonvulsant drugs[J]. Pharmacol Ther, 2007,113(1):165-183.
[16] Chang Y, Yang L Y, Zhang M C, et al. Correlation of the UGT1A4 g ene polymorphism with serum concentration and therapeutic efficacy
of lamotrigine in Han Chinese of Northern China [J]. Eur J Clin Pharmacol, 2014,70(8):941-946.
[17] Barvaliya M J, Patel M K, Patel T K, et al. Toxic epidermal necrolysis
due to lamotrigine in a pediatric patient[J]. J Pharmacol Pharmacother, 2012,3(4):336-338.

77例拉莫三嗪不良反应的文献分析

Literature Review of 77 Cases of Adverse Drug Reactions Induced by Lamotrigine

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[2]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[3]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[4]	郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207.
[5]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[6]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.
[7]	曹桂萍, 邓琳琳, 朱干红, 陆颖, 马爽, 陈玲玲, 刘丽丽. 天麻首乌片致严重肝损伤1例分析[J]. 中国药物警戒, 2024, 21(2): 216-218.
[8]	高云娟, 赵旭, 白天凯, 柏兆方, 王伽伯, 宋海波, 肖小河. 基于不良反应监测大数据的药品安全风险发现与识别策略[J]. 中国药物警戒, 2024, 21(1): 1-5.
[9]	郭龙鑫, 高云娟, 吴承钊, 龙敏娟, 祝胜凯, 宋海波, 赵旭, 肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探[J]. 中国药物警戒, 2024, 21(1): 15-19.
[10]	蒋文硕, 杨莉. 694例癫痫医师药师联合门诊患者药品不良反应分析[J]. 中国药物警戒, 2024, 21(1): 102-106.
[11]	陈华炎, 江东波, 郭春连, 杨家琪, 黎雨欣, 蔡伟明. 326例奈玛特韦片/利托那韦片治疗新型冠状病毒感染安全性分析[J]. 中国药物警戒, 2024, 21(1): 107-110.
[12]	刘赛月, 吕小琴, 周耘. 疑似药品不良反应死亡病例调查及报告实施要点[J]. 中国药物警戒, 2023, 20(9): 971-974.
[13]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[14]	逄瑜, 刘博, 吕少俐, 王涛, 邢颖, 秦星宇, 田月洁, 吴文宇. 基于国际药物警戒经验探讨收集患者报告的意义[J]. 中国药物警戒, 2023, 20(9): 978-981.
[15]	刘文东, 崔欢欢, 王晓晗, 苏娴, 王海学. 我国儿童用药临床试验期间药物警戒监管体系现状及思考[J]. 中国药物警戒, 2023, 20(9): 1002-1006.